Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Beth-Ann Coller"'
Autor:
Bronwyn M. Gunn, Ryan P. McNamara, Lianna Wood, Sabian Taylor, Anush Devadhasan, Wenyu Guo, Jishnu Das, Avlant Nilsson, Amy Shurtleff, Sheri Dubey, Michael Eichberg, Todd J. Suscovich, Erica Ollmann Saphire, Douglas Lauffenburger, Beth-Ann Coller, Jakub K. Simon, Galit Alter
Publikováno v:
Cell Reports, Vol 42, Iss 4, Pp 112402- (2023)
Summary: The 2013 Ebola epidemic in Central and West Africa heralded the emergence of wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against Ebola (rVSVΔG-ZEBOV-GP) will limit future outbreaks, but identifying mech
Externí odkaz:
https://doaj.org/article/90fb68c6d5eb4c3e91f4e4eb1c155d42
Autor:
Igor Morozov, Thomas P. Monath, David A. Meekins, Jessie D. Trujillo, Sun-Young Sunwoo, Kinga Urbaniak, In Joong Kim, Sanjeev K. Narayanan, Sabarish V. Indran, Wenjun Ma, William C. Wilson, Cassandra O'Connor, Sheri Dubey, Sean P. Troth, Beth-Ann Coller, Richard Nichols, Brian K. Martin, Heinz Feldmann, Juergen A. Richt
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 651-663 (2021)
The recent impact of Ebola virus disease (EVD) on public health in Africa clearly demonstrates the need for a safe and efficacious vaccine to control outbreaks and mitigate its threat to global health. ERVEBO® is an effective recombinant Vesicular S
Externí odkaz:
https://doaj.org/article/76a36bca1a3948bfb5561339b098a75b
Autor:
Susan B. Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley, Donna Hyatt, Christine C. Roberts, Jason Lickliter, Janakan Krishnarajah, Andrew Bett, Sheri Dubey, Tyler Finn, Beth-Ann Coller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 9, Pp 2195-2204 (2019)
There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E an
Externí odkaz:
https://doaj.org/article/e4be8a3f1f7443309a7d49c43205d80c
Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program
Publikováno v:
Expert Review of Vaccines, Vol 17, Iss 10, Pp 913-923 (2018)
Introduction: The Ebola epidemic in West Africa from 2014 to 2016 was unique in its size, location, and duration; this article reviews the experiences and lessons learned for one vaccine candidate developed during the outbreak and discusses critical
Externí odkaz:
https://doaj.org/article/e8b59d4bffa845ca8c24d3775f0cff2c
Autor:
Thomas P. Monath, Patricia E. Fast, Kayvon Modjarrad, David K. Clarke, Brian K. Martin, Joan Fusco, Richard Nichols, D. Gray Heppner, Jakub K. Simon, Sheri Dubey, Sean P. Troth, Jayanthi Wolf, Vidisha Singh, Beth-Ann Coller, James S. Robertson
Publikováno v:
Vaccine: X, Vol 1, Iss , Pp - (2019)
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG described live, attenuated, recombinant
Externí odkaz:
https://doaj.org/article/b07b8cb0eee148b0870ad44a4db1f958
Autor:
Jayanthi Wolf, Risat Jannat, Sheri Dubey, Sean Troth, Matthew T. Onorato, Beth-Ann Coller, Mary E. Hanson, Jakub K. Simon
Publikováno v:
Vaccines, Vol 9, Iss 3, p 190 (2021)
Preventative vaccines are considered one of the most cost-effective and efficient means to contain outbreaks and prevent pandemics. However, the requirements to gain licensure and manufacture a vaccine for human use are complex, costly, and time-cons
Externí odkaz:
https://doaj.org/article/94c5c7b69e2a4babbf8d53ab4442cb6a
Autor:
Jason C. Martin, Matthew T. Onorato, Beth-Ann Coller, Kenneth Liu, Rituparna Das, V Study Team, Rick Nichols, Scott A. Halperin, Rebecca J. Grant-Klein, Jakub K. Simon, Frans A. Helmond
Publikováno v:
The Journal of Infectious Diseases
Background This double-blind study assessed immunogenicity, lot consistency, and safety of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVΔG-ZEBOV-GP). Methods Healthy adults (N = 1197) were randomized 2:
Autor:
Kevin Russell, Richard E Rupp, Javier O Morales-Ramirez, Clemente Diaz-Perez, Charles P Andrews, Andrew W Lee, Tyler S Finn, Kara Cox, Amy Falk Russell, Margaret M Schaller, Jason C Martin, Donna M Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann Coller
Publikováno v:
Open Forum Infectious Diseases
Background Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. A dengue vaccine that can be given to both seronegative and seropositive populations remains an importan
Autor:
Sean P. Troth, Heinz Feldmann, Sabarish V. Indran, Sheri Dubey, Sanjeev Narayanan, Juergen A. Richt, Wenjun Ma, Cassandra O'Connor, Jessie D. Trujillo, Richard A. Nichols, Brian K. Martin, Sun Young Sunwoo, Beth-Ann Coller, William C. Wilson, Igor Morozov, Thomas P. Monath, In-Joong Kim, Kinga Urbaniak, David A. Meekins
Publikováno v:
Emerging Microbes & Infections
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The recent impact of Ebola virus disease (EVD) on public health in Africa clearly demonstrates the need for a safe and efficacious vaccine to control outbreaks and mitigate its threat to global health. ERVEBO® is an effective recombinant Vesicular S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e23b3d63e410bbd76c8dfb9759754c6e
Autor:
Jayanthi J. Wolf, Risat Jannat, Beth-Ann Coller, Susan VanRheenen, Michael Eichberg, Sharon Rudo, Samantha Bruno
Publikováno v:
npj Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-5 (2020)
NPJ Vaccines
npj Vaccines, Vol 5, Iss 1, Pp 1-5 (2020)
NPJ Vaccines
The world is experiencing an unprecedented global pandemic of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome-coronavirus-2 (SARS-CoV-2). Development of new vaccines and therapeutics are important